The resubmission follows the FDA's request in May 2009 for the filing to include additional statistical analysis relating to data from one secondary study within the company's filing. Acthar is currently approved in the US for the treatment of multiple sclerosis exacerbations, nephrotic syndrome and many other conditions. Acthar is not approved in the US for the treatment of infantile spasms (IS). Questcor is currently pursuing FDA approval for Acthar in the treatment of IS. Previously, the FDA granted orphan drug designation to Acthar for the treatment of IS. Don Bailey, president and CEO of Questcor, said: "During the past several months we've performed the additional statistical analysis requested by the FDA and look forward to working with the agency during the review process of our resubmission." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon For full details on Questcor Pharmaceuticals (QCOR) click here. Questcor Pharmaceuticals (QCOR) has Short Term PowerRatings of 7. Details on Questcor Pharmaceuticals (QCOR) Short Term PowerRatings is available at This Link.
![]()
Email Print Archives Feedback Email Article Link
Close X
Related News [QCOR]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|